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In Reply
We thank Dizdar [1] for citing two studies [2, 3] in which
dexamethasone was used after or instead of prednisolone
or prednisone for the treatment of patients with meta-
static castration-resistant prostate cancer (mCRPC). Currently,
abiraterone acetate is approved for the treatment of mCRPC
only in combination with prednisone or prednisolone. This
indication is based on the results of two pivotal phase III trials
[4–8] that showed improved survival in the group receiving
combination therapy over prednisone or prednisolone alone.
The author suggests that dexamethasone might offer advan-
tages over prednisone or prednisolone in combination with
abirateroneacetate forcertainpopulationsofmCRPCpatients.
As we emphasized in our review [9], the risks of each regimen
must beweighedagainst thebenefits.Will the “steroid switch”
[2] or monotherapy [3] results with prostate-specific antigen
translate into improved survival when dexamethasone is
combined with abiraterone acetate compared with the Food
and Drug Administration-approved prednisone combination?
A confirmation of this hypothesis can only come with well-
designed and adequately powered prospective clinical studies
comparing the two combinations in the future.
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